ClinicalTrials.gg
RecruitingNCT07400965Updated Feb 27, 2026

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

A Phase 2 interventional study of GLK-321 low dose BID and GLK-321 mid dose BID in Demodex Blepharitis, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Glaukos Corporation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 39 studies in Blepharitis with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Blepharitis · United States.

Planned enrollment
7th of 37
250 · median 60
Started
2025
with 1 other
Phase 2
10 of 39
1 open now
Registered
36th of 39
by date

Among the 39 studies in Blepharitis with a site in United States, this one is the 7th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 in phase 2, and was the 36th registered.

Blepharitis

73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.

Browse Blepharitis studies →

Open to participants now

5 of the 39 studies in Blepharitis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Blepharitis studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Blepharitis with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.

03

Conditions studied

  • Demodex Blepharitis

Browse trials for

Keywords

  • demodex blepharitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signs of Demodex blepharitis in at least one eye
  • Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye

Exclusion criteria

Exclusion Criteria:

  • Presence of eczema or dermatitis in the ocular region of either eye
  • Use of lid hygiene products within 14 days of Screening
  • Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
  • Women who are pregnant, planning a pregnancy, or nursing
  • Have used an drug or device within 30 days prior to Screening or concurrently enrolled in another investigational drug or device trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    GLK-321 low dose BID

    Low dose of GLK-321 administered twice daily (BID) to both eyes

    Drug: GLK-321 low dose BID

  • Experimental
    GLK-321 mid dose BID

    Mid dose of GLK-321 administered twice daily (BID) to both eyes

    Drug: GLK-321 mid dose BID

  • Experimental
    GLK-321 high dose BID

    High dose of GLK-321 administered twice daily (BID) to both eyes

    Drug: GLK-321 high dose BID

  • Experimental
    GLK-321 high dose QD

    High dose of GLK-321 administered once daily (QD) to both eyes

    Drug: GLK-321 high dose QD

  • Placebo comparator
    Placebo BID

    Placebo administered twice daily (BID) to both eyes

    Drug: Placebo BID

Interventions

  • DrugGLK-321 low dose BID

    Twice daily administration of low dose GLK-321 to both eyes

  • DrugGLK-321 mid dose BID

    Twice daily administration of mid dose GLK-321 to both eyes

  • DrugGLK-321 high dose BID

    Twice daily administration of high dose GLK-321 to both eyes

  • DrugGLK-321 high dose QD

    Once daily administration of high dose GLK-321 to both eyes

  • DrugPlacebo BID

    Twice daily administration of placebo to both eyes

06

What researchers measure

Primary outcomes

  1. Percentage of study eyes with elimination of collarettes

    Percentage of study eyes that had eyelash collarettes due to Demodex blepharitis at the onset of treatment who demonstrate absence of collarettes after 6 weeks of treatment

    Time frame: 6 weeks

07

Study locations

1 of 1 sites recruiting
  • Glaukos Clinical Study Site
    Newport Beach, California 92663, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Sep 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Dec 5, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Nov 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07400965
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Dec 5, 2025
Primary completion
Sep 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Study Manager
Contact
ClinicalResearch@Glaukos.com
949-739-8749
Study Director, MD
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion